Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.
Bottom Line: The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).Three subgroup patients with tumour vaccine at 1-year, 2-year and 3-year survival rates also gained significant benefits compared with their corresponding control group (p=0.0004, 0.03 and 0.19, respectively).A few severe adverse effects occurred in the tumour vaccine group, but fewer side effects were observed in the vaccine group compared with the control group (p<0.00001).
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.Show MeSH
Related in: MedlinePlus
Mentions: The data searches yielded a total of 120 references. After referring to the full texts, 79 were considered ineligible for different reasons (5 multiple cancer analyses, 26 reviews, 10 case reports, 23 in vitro experiments and 15 animal models). The remaining 41 articles were further evaluated, and 30 trials were excluded due to language, lack of RCT, different type of lung cancer and insufficient data. As a result, the final 11 articles were included for the meta-analysis. All of the selected studies were RCT and phase II–III clinical trials of tumour vaccine therapy treatment of NSCLC. The screening procedure is shown in figure 1.
Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.